System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Jacopo Canzian is an expert in Oncology at IRCCS Humanitas Research Hospital (Italy). Jacopo Canzian has authored 20 publications, the most recent in 2026. SLR score: 82 (community average: 125). How the SLR is computed.

LeadR Profile

Jacopo Canzian IRCCS Humanitas Research Hospital Italy
82 ScienceLeadR Reputation 82

Unlock

Register Login
Network Map

Oncology

Subspecialties: Hematology - Medical Imaging - Dermatology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2022 - 2027
Source: PubMed

Humanitas University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 20

Citations

Citations: 19 1st author: 4 Last author: 0 Unique author: 0

Main journals

Cancers (Basel) 4
Crit Rev Oncol Hematol 2
ESMO Open 2
Eur J Cancer 2
Tumori 2

Best Journals

Ann Oncol 1
J Clin Oncol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Decluttering chemotherapy agents for HER2+early breast cancer: Do we still need carboplatin?
PMID 42700699 — breast neoplasms, neoplasms, drug therapy, biomarkers, breast, therapeutics, carboplatin, chemotherapy		Eur J Cancer20260
Switching CDK4/6 inhibitors to overcome toxicity in HR-positive/HER2-negative advanced breast cancer.
PMID 42533373 — safety, breast neoplasms, neoplasms, breast		Tumori20260
"Neoadjuvant trastuzumab deruxtecan for high-risk HER2-positive early breast cancer: Does the evidence support its use as a new standard-of-care?".
PMID 42142430 — breast neoplasms, neoplasms, breast, therapeutics, trastuzumab		Eur J Cancer20260
From intravenous to subcutaneous pertuzumab/trastuzumab in breast cancer: Clinical and pharmacoeconomic drivers and barriers to switching.
PMID 41392475 — trust, nurses, safety, breast neoplasms, oncologists, workflow, neoplasms, perception, breast, therapeutics, trastuzumab		Tumori20250
[ 18F]FDG PET/CT as a biomarker for response evaluation in neoadjuvant treatment of early breast cancer: could it become a game-changer in the scenario of the emerging (de)-escalation strategies?
PMID 41324775 — breast neoplasms, tomography, neoplasms, positron emission tomography computed tomography, biomarkers, radiology, fluorodeoxyglucose f18, breast, neoadjuvant therapy, therapeutics		Radiol Med20250

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS